Journal of The Academy of Clinical Microbiologists

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  26 (2024)
Volume  25 (2023)
Volume  24 (2022)
Volume  23 (2021)
Volume  22 (2020)
Volume  21 (2019)
Volume  20 (2018)
Volume  19 (2017)
Volume  18 (2016)
Volume  17 (2015)
Volume  16 (2014)
Volume  15 (2013)
Related articles

VOLUME 25 , ISSUE 2 ( July-December, 2023 ) > List of Articles

Original Article

Molecular detection of urinary microbiome in prostate cancer patients

Shadab Mestri, Satisha Hegde, Makhadumsab Toragall, Sridevi I. Puranik, M. A. Mujeeb, Shridhar C. Ghagane

Keywords : Antibiotic, Escherichia coli, Microbiome, Prostate Cancer, Urine

Citation Information : Mestri S, Hegde S, Toragall M, Puranik SI, Mujeeb MA, Ghagane SC. Molecular detection of urinary microbiome in prostate cancer patients. 2023; 25 (2):44-50.

DOI: 10.4103/jacm.jacm_6_23

License: CC BY-NC 4.0

Published Online: 12-01-2024

Copyright Statement:  Copyright © 2023; Wolters Kluwer India Pvt. Ltd.


Abstract

BACKGROUND: Since the prostate is in the area that is susceptible to infectious agents in Urine, it is rational to hypothesise that infectious agent that causes inflammation may be important in causing Prostate Cancer (PC). To date, there is no single microorganism that is recognised to aid in PC aetiology; yet, various species of bacteria are doubted or known to induce prostatitis, symptomatic bacterial prostatitis-related microbes and pro-inflammatory bacterium. MATERIALS AND METHODS: The left-over Urine samples were collected from patients diagnosed with carcinoma of the prostate attending the Urologic Clinic with a prior consent form after a histopathological diagnosis was performed. The Urine samples were streaked over petri plates (MacConkey and blood agar). Antibiotic susceptibility was conducted using the Kirby-Bauer disc diffusion method, following DNA extraction, polymerase chain reaction and 16s rRNA sequencing of the resistant isolates. IBM SPSS version 20.0 was used for the mean and standard error calculations with percentages. RESULTS: Urine samples showed the presence of polymicrobial isolates (85%), with Escherichia coli being the predominant organism (31.00%). Amongst 48 isolates, 23 were found resistant to antibiotic treatment. The sequencing analysis revealed that E. coli (7) and Klebsiella pneumonia (7) were predominant, followed by Enterococcus faecalis (5), Proteus vulgaris (2), Staphylococcus aureus (1) and Pseudomonas aeruginosa (1). CONCLUSIONS: The Urine analysis revealed polymicrobial isolates, indicating the presence of high microbial flora in men diagnosed with PC, indicating the prevalence of uropathogens and pro-inflammatory bacteria in the urinary tract of PC patients.

PDF Share
  1. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human Microbiome. Genome Med 2016;8:51.
  2. Sethi V, Kurtom S, Tarique M, Lavania S, Malchiodi Z, Hellmund L, et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 2018;155:33-7.e6.
  3. Wang J, Jia H. Metagenome-wide association studies: Fine-mining the Microbiome. Nat Rev Microbiol 2016;14:508-22.
  4. Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The Microbiome in prostate inflammation and Prostate Cancer. Prostate Cancer Prostatic Dis 2018;21:345-54.
  5. Jain S, Saxena S, Kumar A. Epidemiology of Prostate Cancer in India. Meta Gene 2014;2:596-605.
  6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
  7. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
  8. Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, et al. Profiling the urinary Microbiome in men with positive versus negative biopsies for Prostate Cancer. J Urol 2018;199:161-71.
  9. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in Prostate Cancer. Am J Clin Exp Urol 2013;1:3-11.
  10. Klein EA, Silverman R. Inflammation, infection, and Prostate Cancer. Curr Opin Urol 2008;18:315-9.
  11. Collee JG, Fraser AG, Marmion BP, Simmons A. Mackie and McCartney Practical Medical Microbiology. 14th ed. Singapore: Churchill Livingstone Publishers; 2003. p. 1-992.
  12. Clinical Laboratory Standards Institute (CLSI). In: Performance Standard for Antimicrobial Susceptibility Testing. 30th ed. Wayne PA: Clinical Laboratory Standards Institute; 2020. p. 1-293.
  13. Minas K, McEwan NR, Newbold CJ, Scott KP. Optimization of a high-throughput CTAB-based protocol for the extraction of qPCR-grade DNA from rumen fluid, plant and bacterial pure cultures. FEMS Microbiol Lett 2011;325:162-9.
  14. Garibyan L, Avashia N. Polymerase chain reaction. J Invest Dermatol 2013;133:1-4.
  15. Heidler S, Bretterbauer K, Schwarz S, Albrecht W. Diversity of bacterial Urine and prostate gland tissue cultures in patients undergoing transurethral prostate gland resection. Urol Int 2016;97:336-9.
  16. Koeijers JJ, Verbon A, Kessels AG, Bartelds A, Donkers G, Nys S, et al. Urinary tract infection in male general practice patients: Uropathogens and antibiotic susceptibility. Urology 2010;76:336-40.
  17. Sood S, Gupta R. Antibiotic resistance pattern of community acquired uropathogens at a tertiary care hospital in Jaipur, Rajasthan. Indian J Community Med 2012;37:39-44.
  18. Rangari AA, Sharma S, Tyagi N, Singh P, Singh G, Thakur R. Antibiotic susceptibility pattern of bacterial uropathogens isolated from patients at a tertiary care hospital in Western Uttar Pradesh of India. J Curr Microbiol Appl Sci 2015;10:646-57.
  19. Prakash D, Saxena RS. Distribution and antimicrobial susceptibility pattern of bacterial pathogens causing urinary tract infection in urban community of Meerut city, India. ISRN Microbiol 2013;2013:749629.
  20. Gupta S, Kapur S, Padmavathi D. Comparative prevalence of antimicrobial resistance in community-acquired urinary tract infection cases from representative states of Northern and Southern India. J Clin Diagn Res 2014;8:C09-12.
  21. Beyene G, Tsegaye W. Bacterial uropathogens in urinary tract infection and antibiotic susceptibility pattern in Jimma University Specialized Hospital, Southwest Ethiopia. Ethiop J Health Sci 2011;21:141-6.
  22. Yu H, Meng H, Zhou F, Ni X, Shen S, Das UN. Urinary microbiota in patients with Prostate Cancer and benign prostatic hyperplasia. Arch Med Sci 2015;11:385-94.
  23. Cai T, Mazzoli S, Meacci F, Boddi V, Mondaini N, Malossini G, et al. Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol 2011;49:448-54.
  24. Sfanos KS, De Marzo AM. Prostate Cancer and inflammation: The evidence. Histopathology 2012;60:199-215.
  25. Roper WG. The prevention of benign prostatic hyperplasia (BPH). Med Hypotheses 2017;100:4-9.
  26. Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006;313:848-51.
  27. Krieger JN, Dobrindt U, Riley DE, Oswald E. Acute Escherichia coli prostatitis in previously health young men: Bacterial virulence factors, antimicrobial resistance, and clinical outcomes. Urology 2011;77:1420-5.
  28. Murugan K, Savitha T, Vasanthi S. Retrospective study of antibiotic resistance among uropathogens from rural teaching hospital, Tamilnadu, India. Asian Pac J Trop Dis 2012;2:375-80.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.